Enhanced expression of DYRK1A in cardiomyocytes inhibits acute NFAT activation but does not prevent hypertrophy in vivo

Cardiovascular Research

Volumn 90, Issue 3, 2011, Pages 521-528

  Grebe, Cornelia ^a   Klingebiel, Theda Maria ^a   Grau, Simon Philipp ^a   Toischer, Karl ^a   Didié, Michael ^a   Jacobshagen, Claudius ^a   Dullin, Christian ^a   Hasenfuss, Gerd ^a   Seidler, Tim ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Calcineurin; DYRK1A; Hypertrophy; NFAT; Transgenic mice

Indexed keywords

DUAL SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE 1A; PHENYLEPHRINE; PROTEIN KINASE; TETRACYCLINE; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONGENITAL HEART MALFORMATION; CONTROLLED STUDY; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; GENE OVEREXPRESSION; GENE TRANSLOCATION; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HISTOPATHOLOGY; HYPOTHESIS; IN VIVO STUDY; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; CALCINEURIN; CARDIOMEGALY; CELLS, CULTURED; FEMALE; GENE KNOCKDOWN TECHNIQUES; MALE; MICE; MICE, TRANSGENIC; MYOCYTES, CARDIAC; NFATC TRANSCRIPTION FACTORS; PHENYLEPHRINE; PREGNANCY; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; RATS; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION;

EID: 79957474770     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvr023     Document Type: Article

References (30)

1. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-1566. (Pubitemid 20176696)
2. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: The Framingham Study. J Am Coll Cardiol 1993;22:6A-13A. (Pubitemid 23285789)
3. Clerk A, Cullingford TE, Fuller SJ, Giraldo A, Markou T, Pikkarainen S et al. Signaling pathways mediating cardiac myocyte gene expression in physiological and stress responses. J Cell Physiol 2007;212:311-322. (Pubitemid 47025620)
4. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 2006;7:589-600. (Pubitemid 44325350)
5. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998; 93:215-228. (Pubitemid 28180855)
6. Bueno OF, Wilkins BJ, Tymitz KM, Glascock BJ, Kimball TF, Lorenz JN et al. Impaired cardiac hypertrophic response in calcineurin A beta-deficient mice. Proc Natl Acad Sci USA 2002;99:4586-4591. (Pubitemid 34286028)
7. Zou Y, Hiroi Y, Uozumi H, Takimoto E, Toko H, Zhu W et al. Calcineurin plays a critical role in the development of pressure overload-induced cardiac hypertrophy. Circulation 2001;104:97-101. (Pubitemid 32623296)
8. Bourajjaj M, Armand AS, da Costa Martins PA, Weijts B, van der Nagel R, Heeneman S et al. NFATc2 is a necessary mediator of calcineurin-dependent cardiac hypertrophy and heart failure. J Biol Chem 2008;283:22295-22303.
9. Antos CL, McKinsey TA, Frey N, Kutschke W, McAnally J, Shelton JM et al. Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci USA 2002;99:907-912. (Pubitemid 34106609)
10. Molkentin JD. Calcineurin and beyond: Cardiac hypertrophic signaling. Circ Res 2000; 87:731-738.
11. Gwack Y, Sharma S, Nardone J, Tanasa B, Iuga A, Srikanth S et al. A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT. Nature 2006;441:646-650. (Pubitemid 43927297)
12. Arron JR, Winslow MM, Polleri A, Chang CP,Wu H, Gao X et al. NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature 2006;441: 595-600. (Pubitemid 43927286)
13. Smith DJ, Stevens ME, Sudanagunta SP, Bronson RT, Makhinson M, Watabe AM et al. Functional screening of 2 Mb of human chromosome 21q22.2 in transgenic mice implicates minibrain in learning defects associated with Down syndrome. Nat Genet 1997;16:28-36. (Pubitemid 27198153)
14. Altafaj X, Dierssen M, Baamonde C, Marti E, Visa J, Guimera J et al. Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome. Hum Mol Genet 2001;10:1915-1923. (Pubitemid 32910536)
15. Ahn KJ, Jeong HK, Choi HS, Ryoo SR, Kim YJ, Goo JS et al. DYRK1A BAC transgenic mice show altered synaptic plasticity with learning and memory defects. Neurobiol Dis 2006;22:463-472. (Pubitemid 43832120)
16. Kuhn C, Frank D, Will R, Jaschinski C, Frauen R, Katus HA et al. DYRK1A is a novel negative regulator of cardiomyocyte hypertrophy. J Biol Chem 2009;284: 17320-17327.
17. Sanbe A, Gulick J, Hanks MC, Liang Q, Osinska H, Robbins J. Reengineering inducible cardiac-specific transgenesis with an attenuated myosin heavy chain promoter. Circ Res 2003;92:609-616. (Pubitemid 36417694)
18. Seidler T, Teucher N, Hellenkamp K, Unsold B, Grebe C, Kramps P et al. Limitations of FKBP12.6-directed treatment strategies for maladaptive cardiac remodeling and heart failure. J Mol Cell Cardiol 2011;50:33-42.
19. Wilkins BJ, Dai YS, Bueno OF, Parsons SA, Xu J, Plank DM et al. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res 2004;94:110-118. (Pubitemid 38064105)
20. Gockler N, Jofre G, Papadopoulos C, Soppa U, Tejedor FJ, Becker W. Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation. FEBS J 2009;276:6324-6337.
21. Kelly PA, Rahmani Z. DYRK1A enhances the mitogen-activated protein kinase cascade in PC12 cells by forming a complex with Ras, B-Raf, and MEK1. Mol Biol Cell 2005;16:3562-3573. (Pubitemid 41077070)
22. Bueno OF, De Windt LJ, Tymitz KM, Witt SA, Kimball TR, Klevitsky R et al. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. Embo J 2000;19:6341-6350.
23. Yang J, Rothermel B, Vega RB, Frey N, McKinsey TA, Olson EN et al. Independent signals control expression of the calcineurin inhibitory proteins MCIP1 and MCIP2 in striated muscles. Circ Res 2000;87:E61-68.
24. 2+ signal integrators. Proc Natl Acad Sci USA 2008;105:2859-2864. (Pubitemid 351723634)
25. Park J, Oh Y, Chung KC. Two key genes closely implicated with the neuropathological characteristics in Down syndrome: DYRK1A and RCAN1. BMB Rep 2009;42:6-15.
26. Yang EJ, Ahn YS, Chung KC. Protein kinase Dyrk1 activates cAMP response elementbinding protein during neuronal differentiation in hippocampal progenitor cells. J Biol Chem 2001;276:39819-39824.
27. von Groote-Bidlingmaier F, Schmoll D, Orth HM, Joost HG, Becker W, Barthel A. DYRK1 is a co-activator of FKHR (FOXO1a)-dependent glucose-6-phosphatase gene expression. Biochem Biophys Res Commun 2003;300:764-769. (Pubitemid 36268902)
28. de Graaf K, Hekerman P, Spelten O, Herrmann A, Packman LC, Bussow K et al. Characterization of cyclin L2, a novel cyclin with an arginine/serine-rich domain: Phosphorylation by DYRK1A and colocalization with splicing factors. J Biol Chem 2004;279: 4612-4624. (Pubitemid 38199053)
29. Alvarez M, Altafaj X, Aranda S, de la Luna S. DYRK1A autophosphorylation on serine residue 520 modulates its kinase activity via 14-3-3 binding. Mol Biol Cell 2007;18: 1167-1178. (Pubitemid 46626613)
30. Kim EJ, Sung JY, Lee HJ, Rhim H, Hasegawa M, Iwatsubo T et al. Dyrk1A phosphorylates alpha-synuclein and enhances intracellular inclusion formation. J Biol Chem 2006; 281:33250-33257. (Pubitemid 46036707)